Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Unum Therapeutics is a clinical-stage biopharma...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Yopi is an innovative, wearable technology that is both a personal trainer and a V...
Yopi is an innovative, wearable technology that...
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed st...
Momenta Pharmaceuticals is a biotechnology comp...
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on th...
Sinovac Biotech Ltd. is a China-based biopharma...
Alkermes plc is a fully integrated, global biopharmaceutical company developing in...
Alkermes plc is a fully integrated, global biop...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.